Hepatic lipase
LIPCproteinHepatic lipase remodels lipoprotein composition through triglyceride and phospholipid hydrolysis, influencing atherogenic lipoprotein heterogeneity.
Pathway placement
Cascade stepLipid retention & oxidation
Confidencemedium
RationaleTriglyceride and phospholipid hydrolysis; lipoprotein remodeling and composition.
Also acts inSystemic / off-pathway
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000166035
Type I vs non-Type I discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I39
C — non-Type-I52
A — assay feasibility68
E — evidence strength21
T1DI (composite)6
Specificity differential (R−C)-12.4
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(2)
- Hepatic Lipase: a Comprehensive View of its Role on Plasma Lipid and Lipoprotein Metabolism.Journal of atherosclerosis and thrombosis · 2015 · PMID 26194979 · doi
- Lipases as modulators of atherosclerosis in murine models.Current drug targets · 2007 · PMID 18220707 · doi